1-7 of 7
Ada Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801

Free
Dillon H. Miles, Corinne N. Foley, Shiwei Qu, Dillon H. Miles, Srinivas Paladugu, Ehesan U. Sharif, Joice Thomas, Pradeep Nareddy, Guiling Zhao, Rebecca Grange, Manmohan R. Leleti, Jay P. Powers, Stefan Garrido-Shaqfeh, Ada Chen, Hema Singh, Yue Tong Lee, Xiaoning Zhao, David Green, Hsin-Ting Huang, Lixia Jin, Jhansi Leslie, Logan Chinn, Susan L Paprcka, Ester Fernandez-Salas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (12_Supplement): A011.
https://doi.org/10.1158/1538-8514.CANCERCHEM24-A011
Published: 09 December 2024
View articletitled, Abstract A011: Discovery and characterization of the first highly potent and selective AXL receptor tyrosine kinase inhibitor AB801
Journal Articles

Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors

Open Access
Amy E. Anderson, Kaustubh Parashar, Ke Jin, Julie Clor, Carlo E. Stagnaro, Urvi Vani, Jaskirat Singh, Ada Chen, Yihong Guan, Priyanka Talukdar, Pavithra Sathishkumar, Damie J. Juat, Hema Singh, Ritu Kushwaha, Xiaoning Zhao, Angelo Kaplan, Lisa Seitz, Matthew J. Walters, Ester Fernandez-Salas, Nigel P.C. Walker, Christine E. Bowman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (10): 1471–1482.
https://doi.org/10.1158/1535-7163.MCT-23-0865
Published: 01 October 2024
View articletitled, Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors
Open the PDF for Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

Open Access
Dana Piovesan, Joanne B.L. Tan, Annette Becker, Jesus Banuelos, Nell Narasappa, Daniel DiRenzo, Kristen Zhang, Ada Chen, Elaine Ginn, Akshata R. Udyavar, Fangfang Yin, Susan L. Paprcka, Bhamini Purandare, Timothy W. Park, Nikki Kimura, Jaroslaw Kalisiak, Stephen W. Young, Jay P. Powers, Uli Schindler, Kelsey E. Sivick, Matthew J. Walters
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 948–959.
https://doi.org/10.1158/1535-7163.MCT-21-0802
Published: 01 June 2022
View articletitled, Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
Open the PDF for Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Abstract C050: A novel, potent, and selective hypoxia-inducible factor (HIF)-2α antagonist

Free
Kelsey E Sivick Gauthier, Kenneth V Lawson, Dana Piovesan, Matthew J Walters, Ada Chen, Xiaoning Zhao, Cesar Meleza, Nikki Kimura, Tim Park, Steve Young, Anh Tran, Samuel L Drew, Lixia Jin, Manmohan Leleti, Elaine Ginn, Jay P Powers
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C050.
https://doi.org/10.1158/1535-7163.TARG-19-C050
Published: 01 December 2019
View articletitled, Abstract C050: A novel, potent, and selective hypoxia-inducible factor (HIF)-2α antagonist
Journal Articles

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents

Free
Jude Canon, Tao Osgood, Steven H. Olson, Anne Y. Saiki, Rebecca Robertson, Dongyin Yu, John Eksterowicz, Qiuping Ye, Lixia Jin, Ada Chen, Jing Zhou, David Cordover, Stephen Kaufman, Richard Kendall, Jonathan D. Oliner, Angela Coxon, Robert Radinsky
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (3): 649–658.
https://doi.org/10.1158/1535-7163.MCT-14-0710
Published: 09 March 2015
View articletitled, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
Open the PDF for The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia

Free
Kathleen Keegan, Cong Li, Zhihong Li, Ji Ma, Mark Ragains, Suzanne Coberly, David Hollenback, John Eksterowicz, Lingming Liang, Margaret Weidner, Justin Huard, Xianghong Wang, Grace Alba, Jessica Orf, Mei-Chu Lo, Sharon Zhao, Rachel Ngo, Ada Chen, Lily Liu, Timothy Carlson, Christophe Quéva, Lawrence R. McGee, Julio Medina, Alexander Kamb, Dineli Wickramasinghe, Kang Dai
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (4): 880–889.
https://doi.org/10.1158/1535-7163.MCT-13-0858
Published: 06 April 2014
View articletitled, Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Open the PDF for Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract A279: Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor.

Free
Kang Dai, Kathleen Keegan, Zhihong Li, Ma Ji, Cong Li, John Eksterowicz, Coberly Suzanne, David Hollenback, Margret Weidner, Justin Huard, Lingming Liang, Grace Alba, Jessica Orf, Mei-Chu Lo, Sharon Zhao, Rachel Ngo, Ada Chen, Lily Liu, Timothy Carlson, Lawrence R. McGee, Julio Medina, Alexander Kamb, Dineli Wickramasinghe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A279.
https://doi.org/10.1158/1535-7163.TARG-13-A279
Published: 01 November 2013
View articletitled, Abstract A279: Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor.